To understand the consequences of the high prevalence of ARID1A mutations in cancer, we based our analysis on MSK (Memorial Sloan Kettering) cancer panel data as of 2022, containing 1659 bladder cancer samples from 1244 patients [23]. This evidence concerns the gene ARID1A and urinary bladder carcinoma.